Clinical Study
Diagnostic Significance of Serum Eotaxin-1 Level in Gastric Cancer Patients
Table 1
The relationship between s-eotaxin-1 levels and pathologic variables in gastric cancer patients.
| Variables | | S-eotaxin, pg/mL median (interquartile range) | |
| Age, y | | | | <50 | 9 | 81.2 (±13.70) | 0.681 | 50–60 | 12 | 76.8 (±19.56) | >60
| 39 | 72.2 (±16.20) | Sex | | | | Male | 40 | 76.08 (±16.74) | 0.845 | Female | 20 | 71.38 (±16.44) | Tumor localization | | | | Cardia/Fundus | 25 | 74.35 (±15.00) | 0.354 | Corpus | 7 | 79.49 (±18.54) | Antrum | 28 | 73.41 (±17.95) | Differentiation | | | | Well | 9 | 72.08 (±18.53) | 0.299 | Moderate | 12 | 80.26 (±11.62) | Poor | 33 | 73.65 (±18.35) | Undifferentiated | 6 | 71.38 (±12.86) | Tumor size | | | | ≤4 cm | 15 | 78.25 (±14.83) | 0.271 | 4 cm< | 39 | 74.00 (±17.64) | Lymph node metastases (N) | | | | 0 | 9 | 75.82 (±19.19) | 0.823 | I | 8 | 80.15 (±14.26) | II | 17 | 74.09 (±14.51) | IIIA | 11 | 70.51 (±20.02) | IIIB | 11 | 75.59 (±19.03) | Positive lymph node ratio (%) | | | | 0 | 9 | 75.82 (±19.19) | 0.547 | 1–9 | 10 | 80.30 (±13.78) | 10–25 | 12 | 69.67 (±11.74) | 26< | 25 | 74.75 (±19.39) | TNM Stage | | | | I/II (early gastric cancer) | 17 | 78.29 (±15.47) | 0.427 | III/IV (late gastric cancer) | 43 | 73.02 (±17.04) | Perineural invasion | | | | Positive | 46 | 74.40 (±16.67) | 0.831 | Negative | 9 | 74.12 (±18.14) | Vascular invasion | | | | Positive | 46 | 74.77 (±16.76) | 0.898 | Negative | 9 | 72.23 (±17.45) |
|
|